特瑞普利单抗注射液联合OFL方案对胃癌患者sPD-1、sTim-3、sLAG-3水平的影响  

Influence of Toripalimab injection combined with OFL regimen on levels of sPD-1,sTim-3,and sLAG 3 in patients suffering from gastric cancer

作　　者：陈卓 梅馨月 吴思 Chen Zhuo;Mei Xinyue;Wu Si(Department of Oncology,Nanyang Central Hospital,Nanyang,Henan 473000,China)

机构地区：[1]南阳市中心医院肿瘤科,河南南阳473000

出　　处：《齐齐哈尔医学院学报》2024年第12期1136-1139,共4页Journal of Qiqihar Medical University

摘　　要：目的探讨特瑞普利单抗注射液联合OFL方案(奥沙利铂+氟尿嘧啶+亚叶酸钙)对胃癌患者可溶性程序性死亡-1(sPD-1)、可溶性T细胞免疫球蛋白黏蛋白分子-3(sTim-3)、可溶性淋巴细胞活化基因-3(sLAG-3)水平的影响。方法选择2021年1月—2022年12月本院收治的98例胃癌患者作为研究对象,通过抛硬币法随机分为常规组和观察组两组,每组各49例。常规组应用OFL方案化疗,观察组在常规组基础上加用特瑞普利单抗注射液治疗。比较两组临床疗效和药物毒副作用,治疗前后的肿瘤标志物水平及sPD-1、sTim-3、sLAG-3水平,随访12个月的生存状况。结果观察组的客观缓解率(ORR)和疾病控制率(DCR)分别为71.43%和91.84%,较常规组的36.73%和77.55%更高(P<0.05)。治疗6个疗程后两组肿瘤标志物水平及sPD-1、sTim-3、sLAG-3水平均有所降低,且观察组的下降幅度更大(P<0.05)。观察组和常规组的各药物毒副作用发生率比较差异无统计学意义(P>0.05)。随访12个月,观察组生存率为95.92%(47/49),较常规组的81.93%(40/49)更高(χ^(2)=5.018,P=0.025<0.05)。结论对胃癌患者应用特瑞普利单抗注射液联合OFL方案治疗,临床效果明显,降低肿瘤标志物水平及sPD-1、sTim-3、sLAG-3水平,改善随访12个月的生存状况,且不显著增加药物毒副作用,安全性较高。Objective To investigate the effects of Toripalimab injection combined with OFL regimen(oxaliplatin+fluorouracil+calcium folinate)on levels of soluble programmed death-1(sPD-1),soluble T cell immunoglobulin mucin-3 molecule(sTim-3),soluble lymphocyte activation gene-3(sLAG-3)in patients with gastric cancer.Methods Ninety-eight patients suffering from gastric cancer who were admitted to Nanyang Central Hospital from January 2021 to December 2022 were enrolled as study subjects,and they were randomly divided into the routine group and the observation group by coin toss method,with 49 cases in each group.The routine group was treated with OFL regimen chemotherapy,and the observation group was treated with Toripalimab injection on the basis of the conventional group.The clinical efficacy,drug toxicity,tumor marker levels,sPD-1,sTim-3,sLAG 3 levels before and after treatment were compared between the two groups,and the survival conditions were followed up for 12 months.Results The objective response rate(ORR)and disease control rate(DCR)in the observation group were 71.43%and 91.84%,respectively,which were higher than 36.73% and 77.55% in the routine group(P<0.05).After 6 courses of treatment,the levels of tumor markers,sPD-1,sTim-3 and sLAG-3 decreased in both groups,and the declines were greater in the observation group(P<0.05).There was no significant difference in the incidence of side effects between the observation group and the routine group(P>0.05).After 12 months of follow-up,the survival rate of the observation group was 95.92%(47/49),which was higher than 81.93%(40/49)of the routine group(χ^(2)=5.018,P=0.025<0.05).Conclusions The application of Toripalimab injection combined with OFL regimen in the treatment of gastric cancer patients shows obvious clinical effects,decreases the levels of tumor markers and sPD-1,sTim-3,sLAG-3 levels,improves the survival conditions after 12 months of follow-up,and does not significantly increase drug toxicity and side effects,so the safety is high.

关 键 词：特瑞普利单抗注射液 亚叶酸钙 胃癌 可溶性淋巴细胞活化基因-3 

分 类 号：R735.2[医药卫生—肿瘤]